Pharmacokinetic-Pharmacodynamic relationship of NRTIs and its\ud connection to viral escape: An example based on Zidovudine

摘要

In HIV disease, the mechanisms of drug-resistance are only poorly understood. Incomplete suppression of HIV by antiretroviral agents is suspected to be a main reason. The objective of this in silico study is to elucidate the pharmacokinetic origins of incomplete viral suppression, exemplfied for zidovudine (AZT) as a representative of the key class of nucleoside reverse transcriptase inhibitors\ud(NRTIs). AZT, like other NRTIs, exerts its main action through its intracellular triphoshate (AZT-TP) by competition with natural thymidine triphosphate. We developed a physiologically based pharmacokinetic (PBPK) model describing the intracellular pharmacokinetics of AZT anabolites and subsequently established the pharmacokinetic-pharmacodynamic relationship. The PBPK model has been validated against clinical data of different dosing schemes. We reduced the PBPK model to derive a simple three-\udcompartment model for AZT and AZT-TP that can readily be used in population analysis of clinical trials. A novel machanistic, and for NRTIs generic effect model has been developed that incorporates the primary effect of AZT-TP and potential secondary effect of zidovudine monophosphate. The proposed models were used to analyze the e±cacy and potential toxicity of different dosing schemes for AZT. Based on the mechanism of action of NRTIs, we found that drug heterogeneities due to temporal fluctuations\udcan create a major window of unsuppressed viral replication. For AZT, this window was most pronounced for a 600mg/once daily dosing scheme, in which insu±cient viral suppression was observed for almost half the dosing period.